Free Trial

Fmr LLC Purchases 3,963,912 Shares of Avantor, Inc. (NYSE:AVTR)

Avantor logo with Medical background

FMR LLC lifted its stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 557.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,675,283 shares of the company's stock after purchasing an additional 3,963,912 shares during the quarter. FMR LLC owned 0.69% of Avantor worth $120,950,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Tidal Investments LLC increased its holdings in shares of Avantor by 19.6% in the first quarter. Tidal Investments LLC now owns 14,654 shares of the company's stock worth $375,000 after purchasing an additional 2,399 shares during the period. Cetera Advisors LLC bought a new stake in Avantor during the first quarter worth about $249,000. Park Avenue Securities LLC boosted its holdings in shares of Avantor by 5.9% in the 2nd quarter. Park Avenue Securities LLC now owns 45,297 shares of the company's stock worth $960,000 after purchasing an additional 2,522 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Avantor by 222.0% during the 2nd quarter. SG Americas Securities LLC now owns 19,996 shares of the company's stock valued at $424,000 after purchasing an additional 13,786 shares during the last quarter. Finally, Country Trust Bank raised its holdings in shares of Avantor by 16.9% during the 2nd quarter. Country Trust Bank now owns 1,903,911 shares of the company's stock valued at $40,363,000 after buying an additional 274,759 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Analyst Ratings Changes

AVTR has been the subject of several research reports. Barclays cut their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Friday, October 25th. Wells Fargo & Company reduced their target price on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Monday, October 28th. Robert W. Baird lowered their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 28th. UBS Group reduced their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $27.57.

Read Our Latest Analysis on Avantor

Avantor Stock Down 1.7 %

Avantor stock traded down $0.35 during trading hours on Thursday, hitting $20.84. 8,814,921 shares of the stock traded hands, compared to its average volume of 6,489,631. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company has a market cap of $14.18 billion, a PE ratio of 45.30, a PEG ratio of 2.56 and a beta of 1.29. The firm's 50-day moving average price is $22.87 and its two-hundred day moving average price is $23.62. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Avantor Profile

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Featured Stories

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Should you invest $1,000 in Avantor right now?

Before you consider Avantor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.

While Avantor currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines